Publications

1. Vora SA, Wong WW, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, Swanson SK. 9-Year Outcome and Toxicity in Patients Treated with Intensity Modulated Radiation Therapy for Localized Prostate Cancer. J Urol. 2013 Feb 13. [Epub ahead of print] 2304032
   View PubMed
2. Foote RL, Stafford SL, Petersen IA, Pulido JS, Clarke MJ, Schild SE, Garces YI, Olivier KR, Miller RC, Haddock MG, Yan E, Laack NN, Arndt CA, Buskirk SJ, Miller VL, Brent CR, Kruse JJ, Ezzell GA, Herman MG, Gunderson LL, Erlichman C, Diasio RB. The clinical case for proton beam therapy. Radiat Oncol. 2012; 7:174. Epub 2012 Oct 22. 2287846
   View PubMed
3. Wong WW, Schild SE, Vora SA, Ezzell GA, Nguyen BD, Ram PC, Roarke MC. Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e423-9. Epub 2011 Apr 07. 2157467
   View PubMed
4. Wong WW, Vora SA, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, Swanson SK. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Cancer. 2009 Dec 1; 115(23):5596-606. 1957527
   View PubMed
5. Ezzell GA, Burmeister JW, Dogan N, LoSasso TJ, Mechalakos JG, Mihailidis D, Molineu A, Palta JR, Ramsey CR, Salter BJ, Shi J, Xia P, Yue NJ, Xiao Y. IMRT commissioning: multiple institution planning and dosimetry comparisons, a report from AAPM Task Group 119. Med Phys. 2009 Nov; 36(11):5359-73. 1975495
   View PubMed
6. van Elmpt W, Ezzell GA, Orton CG. Point/Counterpoint. EPID dosimetry must soon become an essential component of IMRT quality assurance. Med Phys. 2009 Oct; 36(10):4325-7. 1969947
   View PubMed
7. Chetty IJ, Curran B, Cygler JE, DeMarco JJ, Ezzell G, Faddegon BA, Kawrakow I, Keall PJ, Liu H, Ma CM, Rogers DW, Seuntjens J, Sheikh-Bagheri D, Siebers JV. Report of the AAPM Task Group No. 105: Issues associated with clinical implementation of Monte Carlo-based photon and electron external beam treatment planning. Med Phys. 2007 Dec; 34(12):4818-53. 1891477
   View PubMed
8. Vora SA, Wong WW, Schild SE, Ezzell GA, Halyard MY. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1053-8. Epub 2007 Mar 29. 1832958
   View PubMed
9. Beddar AS, Biggs PJ, Chang S, Ezzell GA, Faddegon BA, Hensley FW, Mills MD. Intraoperative radiation therapy using mobile electron linear accelerators: report of AAPM Radiation Therapy Committee Task Group No. 72. Med Phys. 2006 May; 33(5):1476-89. 1762937
   View PubMed
10. Schild SE, Korte SM, Wong WW, Vora SA, Younggren JA, Ezzell GA. Treatment planning for dose escalation in non-small cell lung cancer (NSCLC). Med Dosim. 2004 Fall; 29(3):196-203. 1674083
    View PubMed
11. Ezzell GA. Shielding evaluation and acceptance testing of a prefabricated, modular, temporary radiation therapy treatment facility. J Appl Clin Med Phys. 2004; 5(4):120-5. 1754196
    View PubMed
12. Galvin JM, Ezzell GA, Eisbrauch A, Yu C, Butler B, XiaoY, Rosen I, Rosenman, J, Sharpe M, Xing L, Xia P, Lomax T, Low D, Palta J. Implementing IMRT in Clinical Practice: a joint document of the American Society for Therapeutic Radiology and Oncology and the American Association of Physicists in Medicine. International Journal of Rad Oncol Biol Phys. 2004; 58:1616-34. 1689010
    View PubMed
13. Ezzell GA, Galvin JM, Low D, Palta JR, Rosen I, Sharpe MB, Xia P, Xiao Y, Xing L, Yu CX. Guidance document on delivery, treatment planning, and clinical implementation of IMRT: Report of the IMRT subcommittee of the AAPM radiation therapy committee. Med Phys. 2003 Aug; 30(8):2089-115. 1413536
    View PubMed
14. Serago CF, Chungbin SJ, Buskirk SJ, Ezzell GA, Collie AC, Vora SA. Initial experience with ultrasound localization for positioning prostate cancer patients for external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2002 Aug 1; 53(5):1130-8. 1315107
    View PubMed
15. Ezzell GA, Chungbin S. The overshoot phenomenon in step-and-shoot IMRT delivery. J Appl Clin Med Phys. 2001 Summer; 2(3):138-48. 1007326
    View PubMed
16. Herbert DE, Ezzell GA, Hendee WR. Medical physics education programs should include an in-depth course in statistics and mathematical modeling of human anatomy and physiology. Med Phys. 2001 May; 28(5):709-11. 1005459
    View PubMed
17. Ezzell GA, Schild SE, Wong WW. Development of a treatment planning protocol for prostate treatments using intensity modulated radiotherapy. J Appl Clin Med Phys. 2001 Spring; 2(2):59-68. 1006570
    View PubMed
18. Ezzell GA, Gaspar L. Application of a genetic algorithm to optimizing radiation therapy treatment plans for pancreatic carcinoma. Med Dosim. 2000 Summer; 25(2):93-7. 1014573
    View PubMed
19. Ezzell GA. A manual algorithm for computing dwell times for two-catheter endobronchial treatments using HDR brachytherapy. Med Phys. 2000 May; 27(5):1030-3. 1014574
    View PubMed
20. Ezzell GA. Limitations of the straight line assumption for endobronchial HDR brachytherapy treatments. Med Phys. 2000; 27:151-3. 1689008
    View PubMed
21. Aref A, Thornton D, Youssef E, He T, Tekyi-Mensah S, Denton L, Ezzell GA. Dosimetric improvements following 3D planning of tangential breast irradiation. International Journal of Rad Oncol Biol Phys. 2000; 48:1569-74. 1689009
    
22. Gaspar LE, Zamorano LZ, Shamsa F, Fontanesi J, Ezzell GA, Yakar DA. Permanent Iodine-125 implants for recurrent malignant gliomas. International Journal of Rad Oncol Biol Phys. 1999; 43:977-82. 1689007
    
23. Aref A, Ezzell G, Chuba P, Thornton D, Aref I. Tangential irradiation of the intact breast: the ABC of the technique. Med Dosim. 1998 Spring; 23(1):15-9. 1021097
    
24. Ezzell GA. Genetic and geometric optimization of three-dimensional radiation therapy treatment planning. Med Phys. 1996 Mar; 23(3):293-305. 1027430
    View PubMed
25. Han I, Ezzell GA, Orton CG. HDR brachytherapy for cancer of the cervix: technique and results. Activity. 1996; (Special Report No. 8):22-7. 1026739
    
26. Maruyama Y, Ezzell G, Porter AT. Afterloading high dose rate intracavitary vaginal cylinder. Int J Radiat Oncol Biol Phys. 1994 Sep 30; 30(2):473-6. 1021489
    View PubMed
27. Ezzell GA. Quality assurance of treatment plans for optimized high dose rate brachytherapy--planar implants. Med Phys. 1994 May; 21(5):659-61. 1021488
    View PubMed
28. Ezzell GA. Evaluation of new re-entrant ionization chambers for high-dose rate brachytherapy calibrations. Endocuriether Hypotherm Oncol. 1993; 9:233-8. 1031229
    
29. Forman J, Orton CG, Ezzell GA, Porter AT. Hyperfractionated three-dimensional conformal radiotherapy for locally advanced adenocarcinoma of the prostate: preliminary results of a biologic dose escalation study. Radiother Oncol. 1993; 27:203-208. 1031230
    View PubMed
30. Hamlet S, Ezzell GA, Aref A. Larynx Motion Associated with Swallowing During Radiation Therapy. International Journal of Rad Oncol Biol Phys. 1993; 28:467-70. 1689003
    
31. Ahmad K, Kim YH, Ezzell GA, Han IH, Orton CG, Porter AT. Reproducibility of multifractionated outpatient high dose rate brachytherapy in carcinoma of the cervix utilizing the Ahmad-Kim positioner. Endocuriether Hypotherm Oncol. 1992; 8:171-3. 1028274
    
32. Ezzell GA. The effect of alternative calibration procedures using NEL 2505/3 ionization chamber. Activity. 1991; 5:42-43. 1038782
    
33. Ezzell GA. Quality assurance in HDR brachytherapy: physical and technical aspects. Activity. 1991; 5:59-68. 1038907
    
34. Ahmad K, Kim YH, Kim H, Orton CG, Ezzell GA, Deppe G, Mesina CF, Warmelink C, Malone J, Malviya V, Christenson C, Han I, Ratanatharathorn V, Herskovic A. Fractionated high dose rate brachytherapy and concomitant teletherapy in the treatment of carcinoma of the cervix: technique and early results. Endocuriether Hypotherm Oncol. 1991; 7:117-24. 1038931
    
35. Ezzell GA. Evaluation of calibration techniques for a high dose rate remote afterloading iridium-192 source. Endocuriether Hypotherm Oncol. 1990; 6:101-6. 1035967
    
36. Ezzell GA. Calibration inter-comparison of an 192-IR source used for high dose rate remote afterloading. Activity. 1989; 1:10-13. 1047272
    
37. Mesina CF, Ezzell GA, Campbell JM, Orton CG. Commissioning the Selectron HDR Co-60. Activity. 1988; 2:5-10. 1044655
    
38. Mesina CF, Ezzell GA, Campbell JM, Orton CG. Acceptance testing for the Selectron high dose rate remote afterloading cobalt-60 unit. Endocuriether Hypotherm Oncol. 1988; 4:253-6. 1044585
    
39. Maughan RL, Blosser HG, Powers WE, Blosser EB, Blosser GF, Vincent J, Ezzell GA, Orton CG, Ragan DP. Progress with the superconducting cyclotron neutron therapy facility for Harper-Grace hospitals. Radiat Prot Dosimetry. 1988; 23:357-60. 1044539
    
40. Campbell JM, Ezzell GA, Herron D, Powers WE, Orton CG. Coded dummy strands for treatment planning of iridium - 192 implants. Endocuriether Hypotherm Oncol. 1988; 5:107-110. 1044540
    
41. Ezzell GA, Orton CG, Maughan RL, Spicka JT, Vitalis TJ, Herskovic AM. Practical aspects of transmission cord blocks in radiotherapy. Med Phys. 1987 May-Jun; 14(3):400-5. 1041305
    View PubMed
42. Herskovic AM, Ezzell GA, Orton CG, Lattin PB, Eisenbrey A, Thomas M, Lazo A, Muz J. Novel applications of phosphorus-32 in the treatment of cystic craniopharyngioma. Endocuriether Hypotherm Oncol. 1986; 2:129-35. 1053305
    
43. Orton CG, Herskovic AM, Ezzell GA, Spicka JT, Vitalis T. Transmission blocks: clinical and biological rationales. Int J Radiat Oncol Biol Phys. 1985 Dec; 11(12):2155-8. 1050546
    View PubMed
44. Vitalis TJ, Reid MD, Orton CG, Ezzell GA, Spicka JT. The application and design of transmission blocks in radiotherapy. American Association of Medical Dosimetrists Newsletter. 1985; 10(Number 2). 1050550